Socioeconomic disparities and the genomic landscape of gastric cancer

Zanabria D.; Galvez-Nino M.; Araujo J.M.; Alfaro A.; Fajardo W.; Saravia L.; Quispe L.; Velazque G.; Carbajal J.; López M.J.; Jimenez S.; Montenegro P.; Zevallos A.; Clavo M.D.L.A.; Medina-Pérez P.; Cornejo M.; Requena M.; Aguilar A.; Pinto J.A. · Scientific Reports (2024) · DOI: 10.1038/s41598-024-65912-6

Resumen

The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration of the possibility that patients from different socioeconomic backgrounds may be exposed to different risk factors. We conducted a prospective pilot study in two Peruvian cities (Lima and Ica). This study enrolled 15 patients from low socioeconomic status (LSES) and 15 patients from medium/high socioeconomic status (MHSES). The genomic profiling of gastric adenocarcinoma samples was done through the FoundationOne CDx platform. We compared the genomic characteristics and the need for targeted therapy and immunotherapy between LSES and MHSES. The genes with higher rates of alterations were TP53 (73.3% vs. 50.0%, P = 0.2635); CDH1 (26.7% vs. 28.6%, P = 1); CDKN2A (20.0% vs. 28.6%, P = 1); KRAS (33.3% vs. 7.1%, P = 0.1686); ARID1A (20.0% vs. 14.3%, P = 1); MLL2 (13.3% vs. 21.4%, P = 1) and SOX9 (33.3% vs. 0.0%, P = 0.0421) in LSES versus HMSES, respectively. There was no significant difference in tumor mutational burden (P = 0.377) or microsatellite status (P = 1). The LSES group had a higher need for targeted therapy or immunotherapy according to gene involvement and alterations. A significant genomic difference exists among patients with gastric adenocarcinoma of different socioeconomic status, which may result in a different need for targeted therapy and immunotherapy. © The Author(s) 2024.

Instituciones: Universidad Nacional San Luis Gonzaga; Universidad Nacional Federico Villarreal; Universidad Privada San Juan Bautista